Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin

Gastrin is the main hormone stimulating gastric acid secretion, but it exerts proliferative and anti-apoptotic actions on various cancer cell types, in addition to its well-known trophic effect on enterochromaffin-like cells. As treatment with proton pump inhibitors (PPIs) increases the biosynthesis and secretion of gastrin, it has been postulated that treatment with PPIs could increase the risk of cancer, especially in Barrett's esophagus, gastric carcinoids, and colorectal cancer (CRC). Some tumors produce gastrin of their own, which can act in an autocrine manner to promote tumor growth. In addition, gastrin is known to foster the tumor microenvironment. However, in spite of these potentially increased cancer risks due to PPI-induced hypergastrinemia, prospective, large-scale cohort studies did not show an increase in CRC prevalence. The question as to why the long-term use of PPIs was not associated with an increased cancer risk of CRC might be answered by the fact that the PPIs antagonized the trophic effects of hypergastrinemia. Furthermore, the blockade of proton pumps or potassium channels in cancer cells could limit the abnormal glycolytic energy metabolism of cancer cells. Apart from their suppressive effect on gastric acids, PPIs exert an anti-tumor effect through the selective induction of apoptosis as well as an anti-inflammatory effect, and they protect cells from developing chemo- or radiotherapeutic resistance. Moreover, the anti-carcinogenic actions of PPIs were augmented with PPI-induced hypergastrinemia. Together with their potential targeted killing of cancer stem cells, these effects demonstrate their potential anti-cancer actions.

Attractive Tomonaga-Luttinger liquid in a quantum spin ladder

We present NMR measurements of a strong-leg spin-1/2 Heisenberg antiferromagnetic ladder compound (C7H10N)2CuBr4 under magnetic fields up to 15 T in the temperature range from 1.2 K down to 50 mK. From the splitting of NMR lines, we determine the phase boundary and the order parameter of the low-temperature (three-dimensional) long-range-ordered phase. In the Tomonaga-Luttinger regime above the ordered phase, NMR relaxation reflects characteristic power-law decay of spin correlation functions as 1/T1∝T(1/2K-1), which allows us to determine the interaction parameter K as a function of field. We find that field-dependent K varies within the 1<K<2 range, which signifies attractive interaction between the spinless fermions in the Tomonaga-Luttinger liquid.

Field-induced freezing of a quantum spin liquid on the kagome lattice

We report (17)O NMR measurements in the S=1/2 (Cu(2+)) kagome antiferromagnet Herbertsmithite ZnCu(3)(OH)(6)Cl(2) down to 45 mK in magnetic fields ranging from 2 to 12 T. While Herbertsmithite displays a gapless spin-liquid behavior in zero field, we uncover an instability toward a spin-solid phase at sub-Kelvin temperature induced by an applied magnetic field. The latter phase shows largely suppressed moments ≲0.1 μ(B) and gapped excitations. The H-T phase diagram suggests the existence of a quantum critical point at the small but finite magnetic field μ(0)H(c)=1.55(25) T. We discuss this finding in light of the perturbative Dzyaloshinskii-Moriya interaction which was theoretically proposed to sustain a quantum critical regime for the quantum kagome Heisenberg antiferromagnet model.

Cancer gene therapy using a novel secretable trimeric TRAIL

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family, is a type II transmembrane cytokine molecule. Soluble TRAIL has been shown to induce apoptosis in a wide variety of cancer cells in vitro and to suppress tumor growth specifically without damaging normal cells and tissues in vivo. In our previous report, we have demonstrated that an artificial gene encoding the polypeptide composed of the three functional elements (a secretion signal, a trimerization domain and an apoptosis-inducing moiety of TRAIL gene sequence) expresses and secretes highly apoptotic trimeric TRAIL into the culture supernatant. Here, as an approach to TRAIL-based cancer gene therapy, we developed an adenoviral vector delivering the gene that encodes our secretable trimeric TRAIL (stTRAIL). This adenovirus (Ad-stTRAIL) potently induced apoptosis in vitro in cancer cell lines such as HeLa, MDA-MB-231, A549, HCT116 and U-87MG. In an animal xenograft tumor model bearing a human glioma cell line U-87MG, intratumoral delivery of Ad-stTRAIL dramatically suppressed tumor growth without showing detectable adverse side effects. Histological analysis revealed that Ad-stTRAIL suppresses tumor growth by inducing apoptotic cell death. Contrary to the known rapid clearance of systemically delivered TRAIL protein from the blood circulation, stTRAIL expressed by Ad-stTRAIL in tumor tissues persisted for more than 4 days. In a comparison of tumor suppressor activity between Ad-stTRAIL and Ad-flTRAIL (delivering the full-length TRAIL gene) after mixing infected cells with uninfected cells and implanting these mixed cells in nude mice, Ad-stTRAIL showed higher tumor suppressor activity than that of Ad-flTRAIL. Our data reveal that a gene therapy using Ad-stTRAIL has a promising potential to treat human cancers including gliomas.

Immunohistochemical localization of eight phospholipase C isozymes in pancreatic islets of the mouse

The possible involvement of phospholipase C (PLC) in the regulation of insulin secretion is not clearly understood and neither its isozymes expressed nor cellular localization in the pancreatic islets is known. By using specific monoclonal antibodies, we have investigated the expression and localization of eight different PLC isozymes, beta1, beta2, beta3, beta4, gamma1, gamma2, delta1, and delta2, in the pancreatic islets of adult mice. Immunohistochemical analysis carried out on paraffin embedded sections showed a distinct pattern of expression for each of the PLC isozymes. In the central part of the islets containing beta cells, a high level of beta4 and moderate levels of beta3 and gamma1 were expressed, whereas PLC-beta1 and -gamma1 were abundantly expressed in the exocrine pancreas. These results demonstrated the heterogeneity in expression of the phospholipase C isozymes in pancreatic islets. It is conceivable that these isozymes are coupled to different receptors and perform selective tasks in the regulation of insulin secretion for glucose homeostasis.

Stenting versus non-stenting after revascularization of chronic total coronary artery occlusion: short- and long-term clinical and angiographic results

OBJECTIVE

To investigate the short- and long-term clinician and angiographic outcome of stenting or angioplasty for chronic total coronary artery occlusion.

METHODS

A total of 95 patients with successful percutaneous transluminal coronary angioplasty (PTCA) for total occlusion coronary artery were identified out of 358 patients undergoing PTCA for chronic total occlusion. Patients were classified into two groups: Group A had selective stenting after successful PTCA and Group B only had PTCA. Clinical cardiac events including acute myocardial infarction (AMI) angina, death, repeat revascularization and angiographic variables were followed and analyzed.

RESULTS

A total of 85 of 95 patients (89%) completed clinical and angiographic follow-up. In group A (n = 42), 1 patient experienced an AMI while in group B, 2 patients experienced AMI and 1 died. In group A, the restenosis rate was 29%, reocclusion rate was 12% and recanularization rate was 19%, as compared to 58%, 22% and 45% respectively in group B (P < 0.001, P < 0.05 and P < 0.001, respectively).

CONCLUSIONS

Selective stent improves short- and long-term clinical and angiographic outcomes and is recommended in cases of chronic total occlusion independent of the primary PTCA results.